NEW YORK--(BUSINESS WIRE)--Medidata, a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry, today announced a multi-year partnership expansion with Catalyst Clinical Research to support their global oncology brand, Catalyst Oncology. This renewal builds upon Catalyst’s existing success with the Medidata Platform and incorporates wider offerings, including Medidata Grants Manager and Medidata AI Intelligent Trials, as Catalyst has grown into a robust and global full-service clinical research organization..

纽约-（商业线）-DassaultSystèmes公司的Medidata和生命科学行业临床试验解决方案的领先供应商，今天宣布与Catalyst clinical Research合作开展多年，以支持其全球肿瘤学品牌，Catalyst oncology。此更新建立在Catalyst在Medidata平台上的现有成功基础上，并结合了更广泛的产品，包括Medidata Grants Manager和Medidata AI Intelligent Trials，因为Catalyst已发展成为一个强大的全球全方位临床研究组织。。

This continued commitment for Medidata Rave EDC, Medidata Rave CTMS, and Medidata Rave eTMF enables Catalyst to run complex clinical trials while simplifying its operations and management. By using these integrated capabilities, and incorporating the expansive elements of Grants Manager and Intelligent Trials, Catalyst can streamline workflows, automate document management, and improve visibility to critical trial metrics..

对Medidata Rave EDC，Medidata Rave CTM和Medidata Rave eTMF的持续承诺使催化剂能够运行复杂的临床试验，同时简化其运营和管理。通过使用这些集成功能，并结合Grants Manager和Intelligent Trials的扩展元素，Catalyst可以简化工作流程，自动化文档管理，并提高关键试验指标的可见性。。

“Medidata remains our preferred partner because of their scalability and skill in managing complex trials,” said Nik Morton, president and chief operating officer, Catalyst. 'Their advanced technology will further support our growth and expansion.'

Catalyst总裁兼首席运营官Nik Morton说：“Medidata仍然是我们的首选合作伙伴，因为它们在管理复杂试验方面具有可扩展性和技能。”他们的先进技术将进一步支持我们的增长和扩张

Catalyst has supported over 150 oncology studies and is currently managing more than 80 next-generation cancer clinical trials today across Phases I-III. With 90% of all oncology approvals last year in the U.S. developed using Medidata software, Catalyst’s use of the Medidata Platform will be critical to their continued expansion.

Catalyst支持150多项肿瘤学研究，目前正在I-III期管理80多项下一代癌症临床试验。去年在美国使用Medidata软件开发的所有肿瘤学批准中，有90%是使用Medidata软件开发的，因此催化剂对Medidata平台的使用对于其持续扩展至关重要。

In addition, Catalyst is excited to leverage Medidata AI, which accesses a dataset spanning more than 20 years to engage a more diverse patient population and accelerate enrollment..

此外，Catalyst很高兴利用Medidata AI，Medidata AI访问跨越20多年的数据集，以吸引更多样化的患者群体并加速注册。。

“Medidata is thrilled to serve as Catalyst’s partner since their first trial in 2019 and be part of their continued success,” said Joan Shaiman, senior vice president, Partners, Medidata. “Their decision to recommit to the core elements of our Platform and adopt broader solutions demonstrates that we have the expertise and capabilities needed to support faster decision-making and accelerate trials to advance cancer research.”.

Medidata合作伙伴高级副总裁Joan Shaiman说：“自2019年首次试用以来，Medidata很高兴能成为Catalyst的合作伙伴，并成为他们持续成功的一部分。“他们决定重新组合我们平台的核心要素并采用更广泛的解决方案，这表明我们拥有支持更快决策和加速试验以推进癌症研究所需的专业知识和能力。”。

About Medidata

关于医学数据

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. With over 20 years of groundbreaking technological innovation across more than 30,000 trials and 9 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world.

Medidata通过数字解决方案为更智能的治疗和更健康的人提供动力，以支持临床试验。通过超过30000项试验和900万名患者的20多年开创性技术创新，Medidata提供行业领先的专业知识，分析支持的见解以及全球最大的患者级历史临床试验数据集。

More than 1 million registered users across 2,100+ customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. The company is a wholly owned subsidiary of Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA), which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

2100多个客户中的100多万注册用户相信Medidata的无缝，端到端平台，以改善患者体验，加速临床突破，并使治疗更快地推向市场。该公司是DassaultSystèmes（Euronext Paris:FR0014003TT8，DSY.PA）的合资子公司，凭借其3DEXPERIENCE平台，以第一个端到端的方式领导个性化医疗时代生命科学的数字转型。科学和商业平台，从研究到商业化。

Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata..

Medidata总部设在纽约市，被Everest集团和IDC公认为领导者。在www.medidata.com上发现更多信息，然后关注我们@medidata。。

About Dassault Systèmes

关于达索系统

Dassault Systèmes, the 3DEXPERIENCE® Company, is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable.

3DEXPERIENCE®公司DassaultSystèmes是人类进步的催化剂。我们为企业和员工提供协作虚拟环境，以想象可持续创新。通过使用我们的3DEXPERIENCE平台和应用程序创建现实世界的虚拟双体验，我们的客户可以重新定义其产品的创建，生产和生命周期管理流程，从而对使世界更具可持续性产生有意义的影响。

The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all –consumers, patients and citizens. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.com..

体验经济的美在于它是一种以人为中心的经济，有利于所有消费者，患者和公民。DassaultSystèmes为150多个国家的所有行业的300000多名客户带来了价值。欲了解更多信息，请访问www.3ds.com。。

© Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under French law, and registered with the Versailles trade and companies registry under number 322 306 440, or its subsidiaries in the United States and/or other countries..

©DassaultSystèmes。版权所有。3DEXPERIENCE，3DS徽标，Compass icon，IFWE，3DEXCITE，3DVIA，BIOVIA，CATIA，CENTRIC PLM，DELMIA，ENOVIA，GEOVIA，MEDIDATA，NETVIBES，OUTSCALE，SIMULIA和SOLIDWORKS是DassaultSystèmes的商业商标或注册商标，根据法国法律注册的欧洲公司（Societas Europaea），并以322 306 440或其在美国和/或其他国家/地区的子公司在凡尔赛贸易和公司注册处注册。。

About Catalyst Clinical Research

关于催化剂临床研究

Catalyst is a clinical research organization (CRO) that provides highly customizable solutions to the global biopharmaceutical industry through two established, branded solutions: Catalyst Oncology and Catalyst Flex. The company provides full-service oncology CRO offerings through Catalyst Oncology and multi-therapeutic Client- or Catalyst-managed functional services through Catalyst Flex.

Catalyst是一家临床研究组织（CRO），通过两种成熟的品牌解决方案为全球生物制药行业提供高度可定制的解决方案：Catalyst Oncology和Catalyst Flex。该公司通过Catalyst oncology和多治疗客户或催化剂管理的功能服务，通过Catalyst Flex提供全方位的肿瘤学CRO产品。

With over 1000 staff and offices in the United States, Europe, and Asia-Pacific regions, Catalyst’s flexible service model is built from more than a decade of listening to customers, devising customer-centric solutions, and helping customers drive breakthrough clinical studies by leveraging expert teams and innovative technologies.

在美国，欧洲和亚太地区拥有1000多名员工和办事处，Catalyst灵活的服务模式建立于十多年来倾听客户的意见，设计以客户为中心的解决方案，并通过利用专家帮助客户推动突破性临床研究团队和创新技术。

Visit Catalyst online at CatalystCR.com. Follow us LinkedIn: @CatalystCR..

访问CatalystCR.com在线催化剂。按照我们的链接：@CatalystCR。。

Catalyst is a portfolio company of QHP Capital, a leading healthcare and life sciences investment firm.

Catalyst是QHP Capital的组合公司，QHP Capital是一家领先的医疗保健和生命科学投资公司。